Wallace Advisory Group LLC Takes $171,000 Position in AstraZeneca PLC (NASDAQ:AZN)

Wallace Advisory Group LLC bought a new position in shares of AstraZeneca PLC (NASDAQ:AZN) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 2,614 shares of the company’s stock, valued at approximately $171,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in AZN. Tealwood Asset Management Inc. raised its position in AstraZeneca by 0.8% during the fourth quarter. Tealwood Asset Management Inc. now owns 37,410 shares of the company’s stock valued at $2,451,000 after acquiring an additional 290 shares in the last quarter. Miracle Mile Advisors LLC grew its stake in shares of AstraZeneca by 445.7% during the 4th quarter. Miracle Mile Advisors LLC now owns 39,986 shares of the company’s stock worth $2,620,000 after purchasing an additional 32,659 shares during the period. Sivia Capital Partners LLC increased its holdings in shares of AstraZeneca by 3.2% during the 4th quarter. Sivia Capital Partners LLC now owns 7,390 shares of the company’s stock valued at $484,000 after purchasing an additional 226 shares in the last quarter. Moody National Bank Trust Division lifted its stake in shares of AstraZeneca by 20.0% in the 4th quarter. Moody National Bank Trust Division now owns 4,556 shares of the company’s stock valued at $299,000 after purchasing an additional 758 shares during the period. Finally, Trust Co. of Toledo NA OH boosted its holdings in AstraZeneca by 4.6% during the fourth quarter. Trust Co. of Toledo NA OH now owns 7,651 shares of the company’s stock worth $501,000 after buying an additional 337 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

AstraZeneca Stock Down 0.5 %

AZN stock opened at $65.37 on Wednesday. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $87.68. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. The firm has a 50-day simple moving average of $65.98 and a 200-day simple moving average of $74.69. The stock has a market capitalization of $202.69 billion, a P/E ratio of 31.28, a P/E/G ratio of 1.19 and a beta of 0.46.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, topping the consensus estimate of $1.01 by $0.03. The company had revenue of $13.57 billion during the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. AstraZeneca’s quarterly revenue was up 18.0% on a year-over-year basis. During the same period in the previous year, the business earned $0.87 EPS. Equities analysts forecast that AstraZeneca PLC will post 4.11 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on AZN shares. UBS Group upgraded shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.